ARTICLE | Clinical News
ImmunoGen posts big gain on ovarian cancer data
June 2, 2015 1:44 AM UTC
ImmunoGen Inc. (NASDAQ:IMGN) surged $6.46 (72%) to $15.44 on Monday after data from a Phase I study showed antibody-drug conjugate mirvetuximab soravtansine ( IMGN853) led to a 53% objective response rate (ORR) among previously treated patients with folate receptor 1 ( FOLR1; FR-alpha)-positive platinum-resistant ovarian cancer. The data were presented at the American Society of Clinical Oncology meeting in Chicago.
In 17 evaluable patients there was one complete response and eight partial responses to the FOLR1-targeting mAb linked to ImmunoGen's DM4 cytotoxic agent. Grade 1 and 2 adverse events (AEs) affecting >20% of patients included diarrhea, blurred vision, nausea, vomiting, fatigue and abdominal pain. ...